Monograph Details
|
|
Infections & Infestations
> Viral infections
|
|
FUZEON |
| Manufacturer |
|
Roche Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Fusion inhibitor. |
| Generic Name |
|
Enfuvirtide 90mg/mL; pwd for SC inj after reconstitution; preservative-free. |
| Indications |
|
Treatment of HIV-1 infection, in combination with other antiretroviral agents, in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. |
| Children |
|
6–16yrs: limited data available; doses of 2mg/kg (max 90mg) twice daily have been used. |
| Adults |
|
Give by SC inj into upper arm, anterior thigh, or abdomen (not into moles, scar tissue, bruises, or navel). ≥16yrs: 90mg twice daily. Rotate inj sites. |
| Precautions |
|
Discontinue if hypersensitivity occurs; do not rechallenge. Monitor for pneumonia (esp. if low initial CD4 cell count, high initial viral load, or smoker). Renal insufficiency (CrCl <35mL/min). Supervise 1st dose. Pregnancy (Cat.B). Nursing mothers: not recommended. |
| Interactions |
|
May cause false (+) ELISA test for HIV. |
| Adverse Reactions |
|
Inj site reactions, diarrhea, nausea, fatigue, insomnia, infections (eg, bacterial pneumonia), peripheral neuropathy, pancreatitis, hypersensitivity reactions (eg, rash, fever, GI upset, elevated ALT/AST, eosinophilia), lab abnormalities (eg, elevated amylase). |
| Extra Text |
|
Note: Register pregnant patients exposed to enfuvirtide by calling (800) 258-4263. |
| How Supplied |
|
Kit—1 (60 vials w. supplies) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
